The Basics

What Are the Types of Mature B-Cell Lymphoma?

This content has been reviewed and approved by
James O. Armitage, MD
The Joe Shapiro Professor of Internal Medicine
Section of Oncology/Hematology
University of Nebraska Medical Center

Diffuse Large B-Cell Lymphoma, Including Mediastinal Large B-Cell Lymphoma


Diffuse large B-cell lymphoma is the most common non-Hodgkin’s lymphoma. The majority of cases include enlarged lymph nodes that can be accompanied by symptoms such as fatigue, fevers, sweats, or weight loss. Approximately one-third of the patients with this disease will have the lymphoma appear in an organ other than lymph nodes.

Essentially any organ in the body can be involved. The gastrointestinal tract is a common site for diffuse large B-cell lymphoma to be found, but lung, kidney, brain, testicle, liver, skin, bones, thyroid, etc. can be the initial site of the disease.

Three specific situations deserve special mention: (1) Diffuse (nonfollicular) large B-cell lymphoma is the most common cancer in the testicles of men over 60. (2) It can also be a brain tumor. This is particularly likely in patients with severe immunosuppression (less ability to fight disease), such as those infected by human immunodeficiency virus (HIV); it is also found in patients with no preceding illness.

Finally, (3) diffuse large B-cell lymphoma that is in the mediastinum in young women is a characteristic disease that has been known for some time. This is often referred to as mediastinal large B-cell lymphoma. It is now known that the genes expressed in these tumors are different from other diffuse large B-cell lymphomas. However, all diffuse large B-cell lymphomas are likely to respond to chemotherapy and many patients will be cured.

Follicular Lymphoma

The second most common non-Hodgkin’s lymphoma in the United States is follicular lymphoma. Symptoms for this disease almost always include enlarged lymph nodes and the disease frequently involves bone marrow. Unlike diffuse large B-cell lymphoma, which is a rapidly growing lymphoma, this tumor tends to progress much more slowly, and patients are less likely to have symptoms such as fevers, sweats, or weight loss. Occasionally, this lymphoma can begin in a site other than lymph nodes.

Over time many patients with follicular lymphoma will have the disease transform to diffuse large B-cell lymphoma. This is a serious complication. Under the microscope, patients with follicular lymphoma have varying numbers of large or transformed lymphocytes in the tumor. Patients with a higher number of large cells in the tumor are more likely to have an aggressive course. The number of large cells in the tumor is estimated by a process called grading. Patients are assigned grade I, grade II, or grade III based on the number of large cells. Patients with grade III are often treated in the same way as those with diffuse large B-cell lymphoma.

Mantle Cell Lymphoma

Mantle cell lymphoma was discovered in the 1990s. Clever pathologists could see some lymphomas that did not fit in the existing categories. The discovery of a specific chromosomal abnormality helped lead to the recognition of this disease.

Mantle cell lymphoma characteristically is found in men between 65 and 70. However, both men and women and younger patients can be affected. The symptoms usually include enlarged lymph nodes. However, the majority of patients will have involvement of bone marrow and the large bowel when a biopsy (tissue sample) is taken. This disease is somewhat more aggressive than follicular lymphoma and until recently did not respond well to available treatments. 

MALT stands for mucosa associated lymphoid tissue. However, the name is somewhat misleading in that not all MALT lymphomas involve mucosa (mucous membrane). They can be found in many sites in the body.

Although the most common site for a MALT lymphoma is the stomach, it can also be found in the tissue around the eye, skin, thyroid, breast, lung, other parts of the gastrointestinal tract, etc. These are among the slowest growing lymphomas. They are frequently localized (confined to one area) and generally have a good prognosis.

Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is a disease involving blood and bone marrow. When patients have lymphadenopathy (abnormally large lymph nodes) or other organ infiltration, the disease is often called small lymphocytic lymphoma. However, it is the same disease. This is usually a slow growing lymphoma, but it is rarely localized. It can occasionally transform to diffuse large B-cell lymphoma (a phenomenon referred to as Richter’s syndrome).

Other Marginal Zone Lymphomas

Two types of lymphoma that are related to MALT lymphomas are nodal marginal zone lymphoma and splenic marginal zone lymphoma. Nodal marginal zone lymphoma progresses much like follicular lymphoma and is a disease that is difficult for pathologists to accurately diagnose.

Splenic marginal zone lymphoma is a relatively rare lymphoma, with symptoms including an enlarged spleen and abnormal lymphocytes in the blood and bone marrow, but rarely with lymphadenopathy. Both of these diseases tend to be relatively slow growing.

Burkitt's Lymphoma

Burkitt's lymphoma is one of the fastest growing cancers. It occurs relatively more frequently in children, but can still be seen in adults. This disease constitutes a medical emergency because it grows so rapidly. Waiting several days to start treatment can have a very bad effect on the chances for cure. Burkitt's lymphoma can involve lymph nodes, bone marrow, or many body organs, including the gastrointestinal tract.

This content was last modified on August 15, 2007 .

Latest Non-Hodgkin's Lymphoma News

  • May 14, 2008
    Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin's Lymphoma
    Patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of optimal survival. These results were recently published in the International Journal of Cancer.
  • May 8, 2008
    Worse Prognosis for “Bulky” Disease Diffuse Large B-Cell Lymphoma
    Young patients with diffuse large-B-cell lymphoma (DLBCL) with cancerous masses that are 10.0 centimeters or greater in diameter are considered to have “bulky” disease and have a worse prognosis than those with smaller masses. These findings were published in Lancet Oncology.
  • May 5, 2008
    Treanda® Included in NCCN Guidelines for CLL and NHL
    The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
Select news items provided by Reuters Health
More Cancer News

Privacy Policy reviewed by TRUSTe

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health
Information:
verify here.

Secure transactions for this website use a thawte certificate to ensure secure transmission of your information.